image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Media Contact:
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Lwolffe@wheelhouselsa.com

Date Title and Summary Additional Format
July 13, 2021 Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in 2021 Strong financial position with $496 million as of May 31, 2021 SAN FRANCISCO, July 13, 2021
June 21, 2021 Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development
SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product
June 2, 2021 Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
June 1, 2021 Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc.
May 21, 2021 Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that
May 11, 2021 Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of Nurix management team will participate in the following conferences in May: RBC Capital Markets Global
April 13, 2021 Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after successful $150 million follow-on offering in March 2021 SAN FRANCISCO, April 13, 2021 (GLOBE NEWSWIRE)
April 7, 2021 Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th
March 16, 2021 Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
March 10, 2021 Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
Displaying 1 - 10 of 17